Article Text

Download PDFPDF
Predictors of 24-month onset of macular fibrosis in type 3 macular neovascularisation
  1. Paolo Forte1,2,
  2. Vincenzo Fontana3,
  3. Julia Muzio2,
  4. Luca Di Cello1,
  5. Paolo Corazza1,2,
  6. Raffaella Rosa1,2,
  7. Donatella Musetti1,2,
  8. Aldo Vagge1,2,
  9. Carlo Enrico Traverso1,2,
  10. Massimo Nicolò1,2,4
  1. 1 IRCCS Ospedale Policlinico San Martino, Eye Unit, Genoa, Italy
  2. 2 DINOGMI, Dipartimento di Neuroscienze, riabilitazione, oftalmologia, genetica e scienze materno-infantili, University of Genoa, Genoa, Italy
  3. 3 IRCCS Ospedale Policlinico San Martino, Clinical Epidemiology Unit, Genoa, Italy
  4. 4 Macula Onlus Foundation, Genoa, Italy
  1. Correspondence to Professor Massimo Nicolò; massimo.nicolo{at}unige.it

Abstract

Aims To explore prognostic multimarker models for progression to macular fibrosis (MF) over 24 months specific to type 3 macular neovascularisation (T3 MNV).

Methods This retrospective, exploratory, single-centre, cohort study comprised 65 eyes of 43 Caucasian patients with treatment naive T3 MNV, all with a 24-month follow-up post anti-VEGF therapy using a strict pro-re-nata (PRN) regimen. Data on demographic features, clinical findings, frequency of intravitreal treatments and optical coherence tomography biomarkers were collected at baseline and after 12 and 24 months of follow-up. Logistic regression models (LRM) and receiver-operating curve (C-index) analyses were performed to evaluate the prognostic ability of the studied biomarkers in discriminating between MF affected and unaffected patients.

Results At final follow-up, MF was present in 46.2% of eyes. Subretinal hyper-reflective material (SHRM) and subretinal pigment epithelium multilaminar hyper-reflectivity (multilaminae) emerged as significant predictors for MF, with adjusted odds ratios (OR) of 18.0 (95% CL 13.4 to 24.1) and 11.8 (95% CL 8.66 to 16.0), respectively. Additionally, the presence of multifocal lesions (OR 0.04, 95% CL 0.01 to 0.30) appeared to decrease the likelihood of MF. C-indexes for the selected LRMs ranged between 0.92 and 0.88, indicating a comparably high discriminant ability. Despite consistent treatment schedules between the two groups (MF: median intravitreal treatment (IVT) number=10.5, IQR=7; non-MF: median IVT=10, IQR=6), a decline in best-corrected visual acuity was noted in the group with MF onset over the 24-month follow-up (−13.0 ETDRS letters; 95% CL –22.1 to –3.9; p=0.006).

Conclusion Our study identifies SHRM and multilaminae as relevant predictors of 24-month onset of MF in patients with T3 MNV. These findings enrich our understanding of the development of MF in T3 MNV and can guide improved risk prognostication. Future research should consider larger samples and prospective designs to validate these predictors.

  • Angiogenesis
  • Hemorrhage
  • Macula
  • Neovascularisation
  • Retina

Data availability statement

Data are available on reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available on reasonable request.

View Full Text

Footnotes

  • Contributors PF, VF, JM and MN: research design, data acquisition and analysis, interpretation of data, drafting the manuscript and critical revision of the manuscript. LDC, PC, RR and DM: data acquisition and analysis, critical revision of the manuscript. AV and CET: interpretation of data and critical revision of the manuscript. MN: guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.